Guideline Video
Guideline Resources
- Title: Nutritional Priorities to Support GLP-1 Therapy for Obesity
- Society: The Obesity Medicine Association (OMA), The American Society for Nutrition (ASN), and The Obesity Society (OS)
- Publish Date: May 30, 2025
- Guideline Summary
- Full-text
Video Transcription
Just published May 30th, 2025 -The American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society’s newest joint advisory on Nutritional priorities to support GLP-1 therapy for obesity.
The objective of this advisory is to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP-1 treatment of obesity for the practicing clinician. It addresses current topics of interest among patients and clinicians, summarizes uncertainties, and highlights future research directions.
There are 3 summary takeaway messages, so let’s get started
- Despite the ability of GLP-1s to produce significant weight reduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, loss of muscle and bone mass, high costs, frequent discontinuation, and weight regain limit the use of these drugs for long-term success in individuals and populations.
- Clinicians prescribing GLP-1s for obesity management should focus on and help mitigate these challenges by developing care plans that include thorough nutritional and lifestyle counseling before, during, and after the weight reduction period.
- Such comprehensive care will support treatment benefits beyond body weight alone and will make clinicians more effective stewards of GLP-1s and, ultimately, of patients' overall health.
Make sure to check out the full guideline from The American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society and other related clinical decision support tools at guidelinecentralcom.
Copyright © 2025 Guideline Central, all rights reserved.